Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Pfizer as the registrant, indicating that no third parties were involved in the filing. The company confirmed that no filing fee was required for this submission. The purpose of the filing and the contents of the additional materials have not been specified in the announcement.

Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Pfizer as the registrant, indicating that no third parties were involved in the filing. The company confirmed that no filing fee was required for this submission. The purpose of the filing and the contents of the additional materials have not been specified in the announcement.